Editas Medicine Inc. Share Price Today: Live Updates & Key Insights

Editas Medicine Inc. share price today is $2.34, up -0.43%. The stock opened at $2.345 against the previous close of $2.35, with an intraday high of $2.445 and low of $2.31.

Editas Medicine Inc. Share Price Chart

Editas Medicine Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Editas Medicine Inc. Share Price Performance

$2.34 -0.0043(-0.43%) EDIT at 23 Mar 2026 12:49 PM Biotechnology
Lowest Today 2.31
Highest Today 2.445
Today’s Open 2.345
Prev. Close 2.35
52 Week High 4.54
52 Week Low 0.91
Day’s Range: Low 2.31 High 2.445
52-Week Range: Low 0.91 High 4.54
1 day return -
1 Week return -8.44
1 month return +21.98
3 month return -
6 month return -22.07
1 year return +67.62
3 year return -67.99
5 year return -95.19
10 year return -

Editas Medicine Inc. Institutional Holdings

Vanguard Group Inc 8.39

BlackRock Inc 8.19

Renaissance Technologies Corp 3.11

Vanguard Total Stock Mkt Idx Inv 3.08

Geode Capital Management, LLC 2.33

iShares Russell 2000 ETF 2.24

Nuveen, LLC 2.02

State Street Corp 1.97

Vanguard Strategic Equity Inv 1.91

Nuveen Quant Small Cap Equity R6 1.71

JPMorgan Chase & Co 1.68

Two Sigma Investments LLC 1.67

Two Sigma Advisers, LLC 1.25

Jane Street Group LLC 1.20

Selectra J. Lamarck Biotech A 1.14

D. E. Shaw & Co LP 1.13

Morgan Stanley - Brokerage Accounts 1.11

Vanguard Institutional Extnd Mkt Idx Tr 1.10

Bank of America Corp 1.05

Fidelity Small Cap Index 0.91

Jacobs Levy Equity Management, Inc. 0.85

Citadel Advisors Llc 0.84

Charles Schwab Investment Management Inc 0.81

iShares Russell 2000 Value ETF 0.81

iShares Biotechnology ETF 0.75

Susquehanna International Group, LLP 0.72

JPM Thematics Genetic Thrps C2 dist USD 0.72

Northern Trust Corp 0.68

AQR Capital Management LLC 0.66

State St Russell Sm/Mid Cp® Indx SL Cl I 0.61

Stifel Financial Corp 0.59

Kennedy Micro Cap 0.57

Schwab US Small-Cap ETF™ 0.49

Fidelity Extended Market Index 0.49

Vanguard Russell 2000 ETF 0.44

Vanguard US Momentum Factor ETF 0.43

Vanguard Strategic Small-Cap Equity Inv 0.42

BlackRock Advantage Small Cap Core Instl 0.34

State St Russell Sm Cap® Indx SL Cl I 0.32

Vanguard Health Care ETF 0.28

Editas Medicine Inc. Market Status

Strong Buy: 4

Buy: 1

Hold: 8

Sell: 2

Strong Sell: 0

Editas Medicine Inc. Fundamentals

Market Cap 229.02 M

PB Ratio 8.3748

PE Ratio 0.0

Enterprise Value 99.99 M

Total Assets 186.53 M

Volume 1780258

Editas Medicine Inc. Company Financials

Annual Revenue FY23:24610000 24.6M, FY22:19712000 19.7M, FY21:25544000 25.5M, FY20:90732000 90.7M, FY19:20531000 20.5M

Annual Profit FY23:null 0.0M, FY22:19712000 19.7M, FY21:25544000 25.5M, FY20:90732000 90.7M, FY19:20531000 20.5M

Annual Net worth FY23:-195083000 -195.1M, FY22:-204352000 -204.4M, FY21:-185107000 -185.1M, FY20:-109412000 -109.4M, FY19:-123466000 -123.5M

Quarterly Revenue Q3/2025:7543000 7.5M, Q2/2025:3578000 3.6M, Q1/2025:4658000 4.7M, Q3/2024:61000 0.1M, Q2/2024:513000 0.5M

Quarterly Profit Q3/2025:7543000 7.5M, Q2/2025:3578000 3.6M, Q1/2025:4658000 4.7M, Q3/2024:-1538000 -1.5M, Q2/2024:-907000 -0.9M

Quarterly Net worth Q3/2025:-25117000 -25.1M, Q2/2025:-53235000 -53.2M, Q1/2025:-76088000 -76.1M, Q3/2024:-62141000 -62.1M, Q2/2024:-67607000 -67.6M

About Editas Medicine Inc. & investment objective

Company Information Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 87

Industry Biotechnology

CEO Dr. Gilmore O'Neill M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Editas Medicine Inc. FAQs

What is the share price of Editas Medicine Inc. today?

The current share price of Editas Medicine Inc. is $2.34.

Can I buy Editas Medicine Inc. shares in India?

Yes, Indian investors can buy Editas Medicine Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Editas Medicine Inc. shares in India?

You can easily invest in Editas Medicine Inc. shares from India by:

Can I buy fractional shares of Editas Medicine Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Editas Medicine Inc.?

Editas Medicine Inc. has a market cap of $229.02 M.

In which sector does Editas Medicine Inc. belong?

Editas Medicine Inc. operates in the Biotechnology sector.

What documents are required to invest in Editas Medicine Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of Editas Medicine Inc.?

The PE ratio of Editas Medicine Inc. is N/A and the PB ratio is 8.37.